Welcome to Axentis Pharma AG

Axentis Pharma AG is a Swiss-based pharmaceutical company focused on value-added anti-infectives in combination with novel inhalation devices. Following the entrance of a License Agreement with a Japanese partner, Axentis Pharma engaged in the development of AX-TOBRA, a liposome-based drug-device combination to combat chronic lung diseases and respiratory disorders, especially cystic fibrosis. AX-TOBRA received Orphan Designations from EU-EMA and US-FDA.

To protect Axentis Pharma against loss and damage from malversation caused by its Japanese partner, Axentis Pharma initiated arbitration proceedings in Tokyo, and, ultimately, won a final and binding Arbitration Award against its former partner. The award was issued by the Japan Commercial Arbitration Association (JCAA) in Tokyo in August 2013. Currently, Axentis Pharma is seeking to enforce the Arbitration Award through judicial remedies.

Meet us at
Axentis Pharma AG - Annual Shareholder Meeting 2016
Rheinfelden, Switzerland
July 6, 2016

Axentis Pharma AG - Annual Shareholder Meeting 2017
Rheinfelden, Switzerland
October 16, 2017

Axentis Pharma AG - Annual Shareholder Meeting 2018
Rheinfelden, Switzerland
November 9, 2018
Axentis Pharma AG
c/o FS Finance Suisse AG
Boersenstrasse 26
8001 Zurich
Phone: +41 44 202 7878

Dr. Helmut Brunar,
Chairman of the Board, eMail

Dr. Rainer Henning,
Board Member, eMail

© 2018 Axentis Pharma AG, Boersenstrasse 26, 8001 Zurich, Phone: +41 44 202 7878